Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial
Lewis EJH, Perkins BA, Lovblom LE, Bazinet RP, Wolever TMS, Bril V
Neurology · 87 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Controlled clinical trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2017-05-18 · Neurology · vol. 88 · issue 24 · pp. 2294–2301
- Publisher
- Lippincott Williams & Wilkins
- Cited
- 114 citations · more than 97% of similar papers · 5.9× the field average
- Impact
- Top 10% most cited in its field
- References
- 39 works
- Access
- Open access (repository copy)
- Research areas
- Fatty Acid Research and Health · Ocular Surface and Contact Lens · Antioxidant Activity and Oxidative Stress
- Keywords
- Medicine, Docosapentaenoic acid, Eicosapentaenoic acid, Polyunsaturated fatty acid, Diabetes mellitus, Docosahexaenoic acid, Type 1 diabetes, Diabetic neuropathy, Sensory nerve, Internal medicine, Polyneuropathy, Endocrinology, Fatty acid, Sensory system, Chemistry, Biology, Biochemistry
- MeSH
- animals, seals, earless, humans, diabetic neuropathies, diabetes mellitus, type 1, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, fatty acids, unsaturated, oils, treatment outcome, follow-up studies, pilot projects, dietary supplements, middle aged, canada, female, male
6 authors
From CA, US
- Evan J.H. LewisMount Sinai Hospital; University Health Network; Sinai Hospital
- Bruce A. PerkinsMount Sinai Hospital; University Health Network; Sinai Hospital
- Leif E. LovblomMount Sinai Hospital; University Health Network; Sinai Hospital
- Richard Paul BazinetMount Sinai Hospital; University Health Network; Sinai Hospital
- Thomas M. S. WoleverMount Sinai Hospital; University Health Network; Sinai Hospital
- Vera BrilMount Sinai Hospital; University Health Network; Sinai Hospital
Abstract
Objective
To test the hypothesis that 12 months of seal oil omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation will stop the known progression of diabetic sensorimotor polyneuropathy (DSP) in type 1 diabetes mellitus (T1DM).
Methods
Individuals with T1DM and evidence of DSP as determined by a Toronto Clinical Neuropathy Score ≥1 were recruited to participate in a single-arm, open-label trial of seal oil ω-3 PUFA supplementation (10 mL·d-1; 750 mg eicosapentaenoic acid, 560 mg docosapentaenoic acid, and 1,020 mg docosahexaenoic acid) for 1 year. The primary outcome was the 1-year change in corneal nerve fiber length (CNFL) measured by in vivo corneal confocal microscopy, with sensory and nerve conduction measures as secondary outcomes.
Results
Forty participants (53% female), aged 48 ± 14 years, body mass index 28.1 ± 5.8 with diabetes duration of 27 ± 18 years, were enrolled. At baseline, 23 participants had clinical DSP and 17 did not. Baseline CNFL was 8.3 ± 2.9 mm/mm2 and increased 29% to 10.1 ± 3.7 mm/mm2 (p = 0.002) after 12 months of supplementation. There was no change in nerve conduction or sensory function.
Conclusions
Twelve months of ω-3 supplementation was associated with increase in CNFL in T1DM.
Clinicaltrialsgovidentifier
NCT02034266.
Classification of evidence
This study provides Class IV evidence that for patients with T1DM and evidence of DSP, 12 months of seal oil omega-3 supplementation increases CNFL.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.